Achillion sets sights on ''best in disease'' regimen for hepatitis C
This article was originally published in Scrip
Executive Summary
Shares in Achillion Pharmaceuticals jumped by 9% on 22 December to $15.49 after it released interim early clinical data from two studies of two hepatitis C drug candidates that it says suggest they could represent a "best in disease regimen" when used together. The company is now planning a Phase II trial of the combination of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422, in 2015.